FY2026 Earnings Estimate for Insmed Issued By HC Wainwright

Insmed, Inc. (NASDAQ:INSM) – Analysts at HC Wainwright issued their FY2026 earnings estimates for Insmed in a research note issued on Wednesday, November 4th. HC Wainwright analyst M. Caufield anticipates that the biopharmaceutical company will post earnings per share of ($1.81) for the year. HC Wainwright has a “Buy” rating and a $220.00 price objective on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.29) EPS, FY2027 earnings at $1.13 EPS, FY2028 earnings at $3.15 EPS, FY2029 earnings at $5.25 EPS and FY2030 earnings at $10.77 EPS.

A number of other equities analysts have also recently commented on the company. BMO Capital Markets reiterated an “outperform” rating on shares of Insmed in a report on Tuesday, October 6th. Wolfe Research downgraded Insmed from an “outperform” rating to a “peer perform” rating in a research report on Monday, October 12th. The Goldman Sachs Group began coverage on Insmed in a research note on Thursday, September 24th. They issued a “buy” rating and a $188.00 price objective on the stock. Truist Financial reaffirmed a “buy” rating and issued a $195.00 price objective (up from $185.00) on shares of Insmed in a research report on Monday, August 10th. Finally, Guggenheim cut their price objective on Insmed from $205.00 to $201.00 and set a “buy” rating for the company in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $196.52.

Insmed Stock Down 1.1%

Shares of INSM stock opened at $108.76 on Friday. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77. The firm’s 50-day moving average is $111.35 and its 200-day moving average is $124.61. Insmed has a 52-week low of $90.39 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to the consensus estimate of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The business’s revenue was up 268.4% on a year-over-year basis. During the same period last year, the business earned ($1.75) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSM. Sei Investments Co. increased its stake in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after purchasing an additional 505,624 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Insmed by 44.0% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,757,541 shares of the biopharmaceutical company’s stock worth $200,845,000 after buying an additional 537,188 shares in the last quarter. NWI Management LP raised its holdings in shares of Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after buying an additional 25,540 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Insmed by 18.8% during the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company’s stock worth $149,860,000 after buying an additional 145,106 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock worth $144,591,000 after buying an additional 1,048,518 shares during the last quarter.

Insider Buying and Selling at Insmed

In other news, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director owned 39,238 shares in the company, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.